

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



石四藥集團有限公司 SSY Group Limited

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2005)

VOLUNTARY ANNOUNCEMENT UPDATE ON PRODUCT DEVELOPMENT

The board of directors (the “Board”) of SSY Group Limited (the “Company”, together with its subsidiaries, the “Group”) is pleased to announce that the National Medical Products Administration of China has approved the passing of Consistency Evaluation of the Quality and Efficacy of Generic Drugs for the Group’s Chlorphenamine Maleate Injection (2ml: 20mg and 1ml: 10mg), in which the 2ml: 20mg specification being the first and 1ml: 10mg specification being the second of respective approvals for the PRC entities.

Chlorphenamine Maleate Injection is mainly used in the treatment of allergic rhinitis, and can also be used for colds or sinusitis, mucocutaneous allergy, and control of drug eruption and contact dermatitis.

This announcement is a voluntary announcement made by the Company to keep the shareholders and potential investors informed of the latest business development of the Group.

By order of the Board
Chow Hing Yeung
Executive Director and Company Secretary

Hong Kong, 9 January 2024

As at the date of this announcement, the Board comprises Mr. Qu Jiguang, Mr. Su Xuejun, Mr. Meng Guo and Mr. Chow Hing Yeung as executive Directors, and Mr. Wang Yibing, Mr. Chow Kwok Wai and Mr. Jiang Guangce as independent non-executive Directors.